|
|
 Previous Article | Table of Contents | Next Article 
The Plasmacytoma Resistance Gene, Pctr2, Delays the Onset of Tumorigenesis and Resides in the Telomeric Region of Chromosome 4
Beverly A. Mock,
Janet Hartley,
Paul Le Tissier,
Judith S. Wax, and
Michael Potter
From the Laboratory of Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; the Laboratory of Immunopathology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD; the Division of Virology, National Institute for Medical Research, The Ridgeway, Mill Hill, London, UK; and PerImmune, Inc, Rockville, MD.
Mouse plasmacytomas share pathogenetic features in common with both multiple myeloma and Burkitt's lymphoma in humans. Susceptibility to plasmacytoma induction by intraperitoneal pristane in mice is controlled by multiple genes. At least two of these genes reside on mouse chromosome 4 in regions of the genome sharing linkage homology with human chromosomes 9p21, 1p32, and 1p36. A series of congenic strains recombinant for regions of mouse chromosome 4 in the vicinity of the Pctr2 predisposition locus were created and typed for their tumor susceptibility/resistance phenotypes. These strains were derived by introgressively backcrossing alleles from resistant DBA/2 mice onto the susceptible BALB/cAnPt background. Six resistant and two susceptible strains were allelotyped for 10 genes and 49 random DNA markers to identify the smallest region of overlap in the resistant strains. These studies have determined that the Pctr2 locus resides in either a 500-kb interval proximal to Nppa, or in a 1- to 2-centiMorgan (cM) interval distal to Nppa. In these congenic strain analyses, the Nppa and Fv1 loci, in addition to genes within about 1 cM of these loci, have been excluded as candidates for the Pctr2 locus. A relevant locus that may reside in this interval is Rep2; it is associated with the efficiency of repairing X-ray induced DNA damage sustained during the G2 phase of the mitotic cycle. The Pctr2 locus acts in a codominant fashion. F1 hybrids between resistant and susceptible congenic strains exhibit a reduced tumor incidence and a significant delay in the onset of tumorigenesis. Identification and eventual cloning of the Pctr2 locus may assist in the identification of genes involved in many types of cancer showing aberrations in human chromosome 1p36.
Blood, Vol. 90 No. 10 (November 15), 1997:
pp. 4092-4098
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Zhang, D. Kagan, W. DuBois, R. Robinson, V. Bliskovsky, W. C. Vass, S. Zhang, and B. A. Mock
Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility
Blood,
October 1, 2009;
114(14):
2952 - 2960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gattenlohner, T. Stuhmer, E. Leich, M. Reinhard, B. Etschmann, H.-U. Volker, A. Rosenwald, E. Serfling, R. C. Bargou, G. Ertl, et al.
Specific Detection of CD56 (NCAM) Isoforms for the Identification of Aggressive Malignant Neoplasms with Progressive Development
Am. J. Pathol.,
April 1, 2009;
174(4):
1160 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Mock, S. Zhang, E. S. Ramsay, V. Bliskovsky, K. Zhang, W. Shi, and W. DuBois
Strategies for Dissecting Complex Traits Associated with Cancer: Lessons from Plasma Cell Tumors
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
273 - 276.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Felix, S. Gerstmeier, A. Kyriakopoulos, O. M. Z. Howard, H.-F. Dong, M. Eckhaus, D. Behne, G. W. Bornkamm, and S. Janz
Selenium Deficiency Abrogates Inflammation-Dependent Plasma Cell Tumors in Mice
Cancer Res.,
April 15, 2004;
64(8):
2910 - 2917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Felix, A. Polack, W. Pretsch, S. H. Jackson, L. Feigenbaum, G.-W. Bornkamm, and S. Janz
Moderate Hypermutability of a Transgenic lacZ Reporter Gene in Myc-Dependent Inflammation-Induced Plasma Cell Tumors in Mice
Cancer Res.,
January 15, 2004;
64(2):
530 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Bliskovsky, E. S. Ramsay, J. Scott, W. DuBois, W. Shi, S. Zhang, X. Qian, D. R. Lowy, and B. A. Mock
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene
PNAS,
December 9, 2003;
100(25):
14982 - 14987.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Dragani
10 Years of Mouse Cancer Modifier Loci: Human Relevance
Cancer Res.,
June 15, 2003;
63(12):
3011 - 3018.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. A. Symons, M. J. Daly, J. Fridlyand, T. P. Speed, W. D. Cook, S. Gerondakis, A. W. Harris, and S. J. Foote
Multiple genetic loci modify susceptibility to plasmacytoma-related morbidity in E{micro}-v-abl transgenic mice
PNAS,
August 20, 2002;
99(17):
11299 - 11304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-L. Zhang, W. DuBois, E. S. Ramsay, V. Bliskovski, H. C. Morse III, L. Taddesse-Heath, W. C. Vass, R. A. DePinho, and B. A. Mock
Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility
Mol. Cell. Biol.,
January 1, 2001;
21(1):
310 - 318.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Dilworth, L. Liu, A. K. Stewart, J. R. Berenson, N. Lassam, and D. Hogg
Germline CDKN2A mutation implicated in predisposition to multiple myeloma
Blood,
March 1, 2000;
95(5):
1869 - 1871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zhang, E. S. Ramsay, and B. A. Mock
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1
PNAS,
March 3, 1998;
95(5):
2429 - 2434.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
